ArticleClinical rheumatology2026
Association between serum uric acid levels and osteoporosis risk: evidence from a cross-sectional study and Mendelian randomization analysis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Approach to Determining Bone Loss Through Serum Uric Acid Levels: A Retrospective Multicenter Cohort Analysis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the relationship between serum uric acid (SUA) levels and osteoporosis (OP) risk through cross-sectional and Mendelian randomization (MR) analyses to address the unclear role of SUA in bone metabolism.
methodsData from the 2015-2020 National Health and Nutrition Examination Survey were analyzed using multiple logistic regression, restricted cubic spline (RCS) modeling, and subgroup analyses. MR was performed using the inverse variance weighted method as the primary approach, complemented by diverse methods and sensitivity analyses.
resultsThis study included 6,020 participants, of whom 1635 were diagnosed with OP. Based on the fully adjusted Model IV, individuals in the third (Q3) and fourth (Q4) quartiles exhibited a 38% (OR = 0.622; 95% CI: 0.423-0.915; P = 0.030) and 49% (OR = 0.513; 95% CI: 0.320-0.823; P = 0.015) lower risk of osteoporosis, respectively, relative to those in the lowest quartile (Q1) (Table 2). RCS analysis revealed an L-shaped inverse association (P-overall = 0.011; P-non-linear = 0.803) with a turning point around 5.3 mg/dL. Subgroup analysis suggested that sex, race, diabetes status, and serum cholesterol levels were potential effect modifiers (P-interaction < 0.05). MR analysis further demonstrated a significant causal protective effect of SUA levels on OP (OR = 0.870; 95% CI: 0.776-0.974, P = 0.016).
conclusionThis study provides new evidence that higher SUA levels are associated with reduced risk of OP, offering potential implications for future preventive strategies. Key Points • Higher serum uric acid levels were independently associated with a lower risk of osteoporosis. • Gender, race, diabetes status, and serum cholesterol levels are factors that affect the negative association between serum uric acid and osteoporosis. • Mendelian randomization analysis supported a causal protective effect of serum uric acid levels on osteoporosis.
Indexed as
Identifiers
41689734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.